EYENOVIA, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 27, 2017Investors’ Rights Agreement • December 19th, 2017 • Eyenovia, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of September 27, 2017, and is between EYENOVIA, INC., a Delaware corporation (the “Company”), the holders of Series A Preferred Stock of the Company as listed on Schedule 1 hereto (the “Series A Investors”), the holders of Series A-2 Preferred Stock of the Company as listed on Schedule 2 hereto (the “Series A-2 Investors”) and the investors listed on Schedule 3 hereto (the “Series B Investors” and together with the Series A Investors and the Series A-2 the “Investors” and each an “Investor”).
July 6th, 2017Eyenovia, Inc. • December 19th, 2017 • Pharmaceutical preparations
On behalf of Eyenovia, Inc. (the “Company”), I am pleased to extend our professional services agreement outlining Cura Partners engagement as an operating Board member, Head of Operations and BD.
EYENOVIA, INC. AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT September 27, 2017Sale Agreement • December 19th, 2017 • Eyenovia, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Right of First Refusal and Co-Sale Agreement (this “Agreement”) is dated as of September 27, 2017, and is between EYENOVIA, INC., a Delaware corporation (the “Company”), the holders of Series A Preferred Stock of the Company as listed on Schedule 1 hereto (the “Series A Investors”), the holders of Series A-2 Preferred Stock of the Company as listed on Schedule 2 hereto (the “Series A-2 Investors”), the investors listed on Schedule 3 hereto (the “Series B Investors” and together with the Series A Investors and the Series A-2 the “Investors” and each an “Investor”), and the holders of the Company’s common stock listed on Schedule 4, as updated from time to time (each a “Holder” and, collectively, the “Holders”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 19th, 2017 • Eyenovia, Inc. • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is made as of March 18, 2015 (the “Effective Date”) by and between Senju Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan, having an office located at 5-8, Hiranomachi 2-chome, Chuo-ku, Osaka 541-0046, Japan (“Senju”) and Eyenovia, Inc., a corporation organized and existing under the laws of Delaware, having a principal place of business at Rivergate Tower 400 N. Ashley St. Suite 2150 Tampa, FL 33602 (“Eyenovia”) Eyenovia and Senju each individually referred to herein as a “Part” and collectively referred to as the “Parties”.
EYENOVIA, INC. AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • December 19th, 2017 • Eyenovia, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED VOTING AGREEMENT (this “Agreement”) is made as of September 27, 2017, by and among EYENOVIA, INC., a Delaware corporation (the “Company”), the holders of Series A Preferred Stock of the Company as listed on Schedule 1 hereto (the “Series A Investors”), the holders of Series A-2 Preferred Stock of the Company as listed on Schedule 2 hereto (the “Series A-2 Investors”), the investors listed on Schedule 3 hereto (the “Series B Investors” and together with the Series A Investors and the Series A-2 the “Investors” and each an “Investor”), and the holders of the Company’s common stock listed on Schedule 4, as updated from time to time (each a “Holder” and, collectively, the “Holders”). The Holders and the Investors are referred to herein collectively as the “Voting Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Company’s Second Amended and Restated Certificate of Incorporation, dated as of the dat
MASTER CONSULTING SERVICES AGREEMENTMaster Consulting Services Agreement • December 19th, 2017 • Eyenovia, Inc. • Pharmaceutical preparations • Florida
This Agreement, effective as of November 4, 2014 (the “Effective Date”), is by and between Private Medical Equity, S-Corp (PME)) with an address at 315 Montgomery Street, Suite 900, San Francisco CA 94104 ("The Party") and EYENOVIA, INC 400 N. Ashley Dr., Suite 2150, Tampa, FL 33602 (“Client”). PME and Client shall individually be referred to as a “Party” and collectively as the “Parties”.
MASTER CONSULTING SERVICES AGREEMENTMaster Consulting Services Agreement • December 19th, 2017 • Eyenovia, Inc. • Pharmaceutical preparations • Florida
This Agreement, effective as of November 4, 2014 (the “Effective Date”), is by and between Point Guard Partners, LLC, with an address at 400 N. Ashley Dr., Suite 2150, Tampa, FL 33602 (“Point Guard”) and EYENOVIA, INC 400 N. Ashley Dr., Suite 2150, Tampa, FL 33602 (“Client”). Point Guard and Client shall individually be referred to as a “Party” and collectively as the “Parties”.
